Allogene Therapeutics Inc (NASDAQ: ALLO) on Friday, soared 1.59% from the previous trading day, before settling in for the closing price of $1.26. Within the past 52 weeks, ALLO’s price has moved between $0.86 and $3.78.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 6.26%. The company achieved an average annual earnings per share of 23.59%. With a float of $149.51 million, this company’s outstanding shares have now reached $218.60 million.
Considering the fact that the conglomerate employs 229 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 100.0%, operating margin of 1222209.09%, and the pretax margin is 1144909.09%.
Allogene Therapeutics Inc (ALLO) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Allogene Therapeutics Inc is 31.65%, while institutional ownership is 65.99%. The most recent insider transaction that took place on Jun 10 ’25, was worth 52,377. In this transaction Director of this company sold 36,885 shares at a rate of $1.42, taking the stock ownership to the 107,431 shares. Before that another transaction happened on Jun 10 ’25, when Company’s Director proposed sale 36,885 for $1.42, making the entire transaction worth $52,391.
Allogene Therapeutics Inc (ALLO) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.24 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 23.59% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.47% during the next five years compared to 6.26% growth over the previous five years of trading.
Allogene Therapeutics Inc (NASDAQ: ALLO) Trading Performance Indicators
Allogene Therapeutics Inc (ALLO) is currently performing well based on its current performance indicators. A quick ratio of 9.71 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.23, a number that is poised to hit -0.27 in the next quarter and is forecasted to reach -0.99 in one year’s time.
Technical Analysis of Allogene Therapeutics Inc (ALLO)
Compared to the last year’s volume of 4.29 million, its volume of 5.26 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 68.09%.
During the past 100 days, Allogene Therapeutics Inc’s (ALLO) raw stochastic average was set at 14.32%, which indicates a significant decrease from 77.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0835 in the past 14 days, which was lower than the 0.1610 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2563, while its 200-day Moving Average is $1.8969. Nevertheless, the first resistance level for the watch stands at $1.3217 in the near term. At $1.3633, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.3967. If the price goes on to break the first support level at $1.2467, it is likely to go to the next support level at $1.2133. Should the price break the second support level, the third support level stands at $1.1717.
Allogene Therapeutics Inc (NASDAQ: ALLO) Key Stats
Market capitalization of the company is 279.98 million based on 218,731K outstanding shares. Right now, sales total 20 K and income totals -257,590 K. The company made 0 K in profit during its latest quarter, and -59,730 K in sales during its previous quarter.
